Skip to main content
. 2012 Feb 13;7(2):e31279. doi: 10.1371/journal.pone.0031279

Figure 3. ILK gene therapy prevents left ventricular dilation, remodeling and interstitial fibrosis in doxorubicin-induced heart failure.

Figure 3

A, Specimens showing effect of ILK treatment on heart size and shape following doxorubicin. B, Hematoxylin-eosin staining of myocardial sections 4 weeks after adeno-ILK or adeno-null treatment, with analysis of cardiac remodeling by quantification of left ventricular (LV) diameter and wall thickness. n = 6 per group. C, Myofilament density and cardiomyocyte size in adeno-ILK and adeno-null groups. n = 6 per group. Scale bars: 100 µm (left panels, 200×), 50 µm (right panels, 400×). D, Masson's trichrome staining showing infiltration by inflammatory cells and myocardial fibrosis in adeno-ILK and adeno-null animals. n = 6 per group. Scale bars: 5 mm. * P<0.05 vs. adeno-null.